Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Amgen's share price saw a 22% rise over three years, lagging behind the broader market's returns. During this period, Amgen's ...

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The Dividend Harvesting Portfolio hit new all-time highs, delivering a 29.44% return. Learn more about the portfolio and why ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...